Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
PROSTVAC-F
BIOLOGICAL
4 trials
Sponsors
Bavarian Nordic
, National Cancer Institute (NCI)
, Washington University School of Medicine
Conditions
Metastatic Hormone-Sensitive Prostate Cancer
Neoplasms, Prostatic
Prostate Cancer
Prostate Cancer Metastatic
Prostate Neoplasms
Phase 1
Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Completed
NCT03532217
Washington University School of Medicine
Metastatic Hormone-Sensitive Prostate Cancer
Start: 2018-09-14
End: 2022-07-25
Updated: 2022-08-05
Phase 2
Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Completed
NCT02649439
National Cancer Institute (NCI)
Prostate Cancer
Start: 2015-12-22
End: 2022-10-01
Updated: 2022-11-14
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Completed
NCT02649855
National Cancer Institute (NCI)
Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms
Start: 2016-01-19
End: 2023-12-05
Updated: 2024-08-06
Phase 3
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Completed
NCT01322490
Bavarian Nordic
Prostate Cancer Metastatic
Start: 2011-11-28
End: 2017-12-15
Updated: 2019-09-04
Related Papers
Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.
Journal of Clinical Oncology
2023-02-20
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology
2022-06-01
8 citations
PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).
Journal of Clinical Oncology
2022-06-01
1 citations
Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.
Journal of Clinical Oncology
2022-02-16
3 citations
Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).
Journal of Clinical Oncology
2021-05-20
1 citations
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology
2021-02-20
5 citations
Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.
Journal of Clinical Oncology
2019-05-20
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
Journal of Clinical Oncology
2019-03-01
3 citations
Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.
Journal of Clinical Oncology
2018-05-20
16 citations
Immunotherapy for biochemically recurrent prostate cancer.
Journal of Clinical Oncology
2018-02-20
6 citations
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology
2015-05-20
17 citations
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
2014-10-14
15 citations
Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.
Journal of Clinical Oncology
2014-02-01
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
Journal for ImmunoTherapy of Cancer
2014-01-01
2 citations